Clinical Trial Detail

NCT ID NCT03179930
Title Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Hodgkin's lymphoma

follicular lymphoma

Therapies

Entinostat + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.